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Snake venom metalloproteinase (SVMP)
Vascular permeability
Background: Envenoming by Bothrops jararaca can result in local pain, edema, hemorrhage and necrosis, par-
tially mediated by snake venom metalloproteinases (SVMPs). Here, we describe the characterization of
BJ-PI2, a P-I class SVMP from B. jararaca venom, and its local tissue actions.
Methods: BJ-PI2 was puriﬁed by a combination of gel ﬁltration, anion-exchange chromatography and reverse
phase HPLC, and identiﬁed by mass spectrometry. Clotting and ﬁbrin(ogen)olytic activities were assayed
using conventional methods. Hemorrhagic activity and changes in vascular permeability were examined in
rat dorsal skin. Myonecrosis and inﬂammatory activity were examined in mouse gastrocnemius muscle.
Results: BJ-PI2 was a 23.08 kDa single-chain polypeptide. Tryptic fragments showed highest homology with
SVMP insularinase A from Bothrops insularis, but also with B. jararaca SVMP bothrojaractivase; less similarity
was observed with B. jararaca SVMPs BJ-PI and jararaﬁbrases II and IV. BJ-PI2 did not clot ﬁbrinogen or rat
citrated plasma but had α- and β-ﬁbrinogenolytic activity (inhibited by EDTA and 1,10-phenanthroline but
not by PMSF) and attenuated coagulation after plasma recalciﬁcation. BJ-PI2 had ﬁbrinolytic activity. BJ-PI2
increased the vascular permeability of rat dorsal skin (inhibited by 1,10-phenanthroline). BJ-PI2 was not
hemorrhagic or myonecrotic but caused migration of inﬂammatory cells. In contrast, venom was strongly
hemorrhagic and myonecrotic but caused less inﬁltration of inﬂammatory cells.
Conclusions: BJ-PI2 is a non-hemorrhagic, non-myonecrotic, non-coagulant P-I class SVMP that may enhance
vascular permeability and inﬂammatory cell migration in vivo.
General signiﬁcance: BJ-PI2 contributes to enhanced vascular permeability and inﬂammatory cell migration
after envenoming, but not to venom-induced hemorrhage and necrosis.© 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Snake venommetalloproteinases (SVMPs) belong to theM12 family
of proteases and are subdivided into three classes: P-I, P-II and P-III [1].
P-I SVMPs consist of proteins containing only a metalloproteinase do-
main while P-II and P-III SVMPs contain metalloproteinase and
disintegrin domains, and metalloproteinase, disintegrin, cysteine-rich
and C-type lectin domains, respectively. The metalloproteinase domain
consists of a conserved amino acid sequence HEXXHGXXH that may
provide the hydrophobicity needed to immobilize a zinc atom [2].
SVMPs are associated with hemostatic disturbances, primarily blood
incoagulability through interference with the coagulation cascade, and
local and systemic hemorrhage through damage to blood vessels and
thrombosis [2–4].
Transcriptomic and proteomic studies have shown that
metalloproteinases are the most abundant components in Bothrops
venom glands and venoms (see [5] and references therein), which: +55 19 3289 2968.
.
vier OA license. suggest an important role for these SVMPs in envenoming by these
snakes. Indeed, part of the local pain, edema, inﬂammation, hemor-
rhage and necrosis, as well as systemic effects such as coagulopathy
and systemic hemorrhage seen after envenoming by Bothrops snakes
[6–9] have been associatedwith the action of SVMPs [10–14]. SVMPs,
such as BaP1, a metalloproteinase from Bothrops asper venom, exert
many of their local effects by activating inﬂammatory immune cells
to release pro-inﬂammatory cytokines (IL-1β and IL-6) [15] and me-
diators such as prostaglandins, e.g., PGE2 [16,17].
Severalmetalloproteinases have been isolated from Bothrops jararaca
venom, themost studied so far being jararhagin [18], a 52 kDaP-III SVMP
with ﬁbrino(geno)lytic and hemorrhagic activity initially puriﬁed and
characterized by Maruyama et al. [19]. Jararhagin degrades extracellular
matrix (ECM) proteins such as laminin, ﬁbronectin and type IV collagen,
stimulates the production of IL-1β, IL-6 and TNF-α and inhibits collagen-
dependent platelet aggregation and vonWillebrand factor (vWF) degra-
dation [18]. Other P-III SVMPs isolated from B. jararaca venom include
hemorrhagic factor 3 (HF3) [20–26] and bothropasin [24,27–29]. Some
P-I SVMPs have also been isolated from B. jararaca venom. Maruyama
et al. [19,30] studied a group of P-I SVMPs collectively known as
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hemorrhagic activity that could be inhibited by EDTA and 1,10-
phenanthroline. These SVMPs also degraded ECM proteins such as lami-
nin, ﬁbronectin and type IV collagen.More recently, two other P-I SVMPs
have been puriﬁed from this venom: BJ-PI, a highly proteolytic
(caseinolytic) enzyme with no hemorrhagic activity in mice [24], and
bothrojaractivase [31], which has strong ﬁbrino(geno)lytic activity and
is a prothrombin activator. Although the enzymatic activity of these en-
zymes is relatively well studied their actions in vivo remain unclear.
In this work, we describe the puriﬁcation and characterization from
B. jararaca venom of BJ-PI2, a non-hemorrhagic, non-myonecrotic
metalloproteinasewith ﬁbrin(ogen)lytic activity that increases vascular
permeability and stimulates the migration of inﬂammatory cells into
damaged tissue. This protein may contribute to the local edema and in-
ﬂammatory response seen after envenoming by B. jararaca.
2. Materials and methods
2.1. Reagents and venom
Bovine serum albumin, casein, elastin-Congo red, ﬁbrinogen
(bovine, plasminogen-free), n-t-boc-L-alanine p-nitrophenyl ester,
1,10-phenanthroline and human thrombin were from Sigma Chemi-
cal Co. (St. Louis, MO, USA). Phenylmethylsulphonyl ﬂuoride (PMSF)
was from Calbiochem (La Jolla, CA, USA) and EDTA was from
Mallinckrodt-Baker (Phillipsburg, NJ, USA). Low-melting point aga-
rose was from USB (Santa Clara, CA, USA). Reagents for electrophore-
sis, molecular mass markers and column chromatography media
(Superdex 75 and Sepharose Q) were from GE Healthcare Life Sci-
ences (Piscataway, NJ, USA). Isoﬂurane and sodium thiopental were
from Cristália (Itapira, SP, Brazil). Other reagents were of analytical
grade obtained from local suppliers.
Venom from adult B. jararaca snakes of both sexes was obtained
from the Centro de Extração de Toxinas Animais (CETA, Morungaba,
SP, Brazil) and stored lyophilized at −20 °C.
2.2. Animals
Male Wistar rats (300–400 g) and male Swiss mice (20–30 g) were
obtained from the Multidisciplinary Center for Biological Investigation
(CEMIB) at UNICAMP. The animals were housed in standard plastic
cages with a wood shaving substrate (5/cage for rats and 10/cage
for mice) at 23 °C on a 12 h light/dark cycle (lights on at 6 a.m.) and
free access to food and water. The animal protocols were approved by
an institutional Committee for Ethics in Animal Use (CEUA/UNICAMP,
protocol no. 2253–1) and the experiments were done according to the
general ethical guidelines for animal use established by the Brazilian So-
ciety of Laboratory Animal Science (SBCAL) and EC Directive 86/609/EEC
for Animal Experiments.
2.3. Puriﬁcation protocol
Venom (100 mg) dissolved in 2 ml of 0.01 M Tris–HCl, pH 8.0,
containing 0.01 M CaCl2 and 0.15 M NaCl was centrifuged (12,000 g,
12 min, 4 °C) and the supernatant was applied to a columnFig. 1. Puriﬁcation of BJ-PI2 from B. jararaca venom. (A) Gel ﬁltration (Superdex 75) elution
activity. The column was equilibrated and eluted (0.5 ml/min) with 0.01 mM Tris–HCl, pH
280 nm. (■) protein, (●) caseinolytic activity. (B) Electrophoretic proﬁle (SDS-PAGE) of pr
mass markers. Silver-stained 15% polyacrylamide gel. (C) Anion exchange chromatograph
Hitrap Sepharose Q column equilibratedwith 0.01 M Tris–HCl, pH 8.0, containing 0.01 M C
the elution proﬁle was monitored at 280 nm. Fractions of 0.5 ml were collected. (■) prote
elution of BJ-PI2. (D) SDS-PAGE of puriﬁed BJ-PI2. Samples were run in a 15% gel and then s
of BJ-PI2. Proteins were eluted with a linear gradient (0–100%) of acetonitrile in 0.1% TFA and t
and reducing conditions. Lane 1 — non-reducing conditions, Lane 2— in the presence of 0.1% (
Reducing agents did not alter themolecular mass of BJ-IP2, indicating that the proteinwas amo
ovalbumin, 30— carbonic anhydrase, 20.1— soybean trypsin inhibitor, 14.4— α-lactalbumin.(16 cm×60 cm) of Superdex 75 previously equilibrated with the
same buffer at 18 °C. The column was eluted at a ﬂow rate of
0.5 ml/min and the elution proﬁle was monitored at 280 nm using
an ÄKTAprime chromatographic system. The fractions were assayed
for caseinolytic activity and those corresponding to the secondmajor
peak containing caseinolytic activity were pooled and concentrated
by centrifugation (3000 g, 30 min, 4 °C) in Amicon ultraﬁlters
(Millipore) to remove NaCl prior to the next step.
The enzyme concentrate obtained in the previous step was diluted
with 0.01 M Tris–HCl, pH 8.0, containing 0.01 M CaCl2 and applied to
a 5 ml HiTrap Sepharose Q column equilibrated with the same buffer.
The column was washed (0.5 ml/min) with Tris–HCl/Ca2+ buffer to
remove unbound proteins and bound proteins were then eluted
with a linear gradient (0–0.5 M) of NaCl and the elution proﬁle was
monitored at 280 nm. Fractions corresponding to the peak with
caseinolytic activity that eluted before the gradient were pooled and
concentrated by centrifugation (3000 g, 30 min, 4 °C) in Amicon
ultraﬁlters (Millipore) to remove NaCl prior to the next step.
Reverse-phase HPLC (RP-HPLC) of the peak from the previous step
was done using a Jupiter C18 column (250 mm×4.6 mm×5 μm;
300 Å; Phenomenex, Torrance, CA, USA) coupled to a Shimadzu
chromatographic system that consisted of two pumps (LC10AD VP),
a UV/Vis detector (SPD-10A), a fraction collector (FRC-10A) and a sys-
tem controller (SCL-10A VP). The column was initially equilibrated
with 0.1% triﬂuoroacetic acid (TFA). The sample was dissolved in H2O
with 0.1% TFA. Proteins were eluted with a linear gradient (0–100%)
of 99.9% acetonitrile in 0.1% TFA and the elution proﬁle was monitored
at 280 nm.
The purity of the protein was assessed by SDS-PAGE and mass
spectrometry.
2.4. Sodium docecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was done in a discontinuous system with a 4% poly-
acrylamide stacking gel prepared in 0.5 M Tris–HCl, pH 6.8,
containing 0.4% SDS, and a 15% running gel prepared in 1.5 M Tris,
pH 8.8, containing 0.4% SDS [32]. The samples were diluted in sample
buffer containing 4% bromophenol blue, 0.06 M Tris–HCl, 2% SDS and
10% glycerol and boiled for 5 min prior to loading onto the stacking
gel. In some cases, 0.1% dithiothreitol or β-mercaptoethanol was
added to the samples before boiling. The gels (10 cm×12.5 cm)
were run in a mini-VE 206E system (GE LifeSciences) at constant
voltage (100 V), with 0.625 M Tris–HCl, 1.92 M glycine and 1% SDS,
pH 6.8, as the running buffer. Molecular mass markers were included
in all runs. After electrophoresis, the gels were stained either with
Coomassie brilliant blue or silver nitrate and documented.
2.5. 2D-polyacrylamide gel electrophoresis
Venom (300 μg) or BJPI-2 (50 μg)was dissolved in 250 μl of rehydra-
tion solution (7 M urea, 2 M thiourea, 2% CHAPS, 0.5% immobilized pH
gradient (IPG) buffer (GE Healthcare Life Sciences) and 1% bromophenol
blue) and precast IPG isoelectric focusing (IEF) strips (13 cm, pH 3–10
linear) were soaked in this solution prior to the ﬁrst dimension of elec-
trophoresis (IEF) in a Multiphor II System (GE Healthcare Life Sciences),proﬁle of B. jararaca venom showing the two major peaks (1 and 2) with caseinolytic
8.0, containing 0.01 M CaCl2 and 0.15 M NaCl. The elution proﬁle was monitored at
oteins in the venom (Lane 2), peak 1 (Lane 3) and peak 2 (Lane 4). Lane 1—molecular
y of the second caseinolytic peak from the ﬁrst step. The sample was applied to a 5 ml
aCl2. The columnwas eluted (0.5 ml/min) with a linear gradient of NaCl (0–0.5 M) and
in content, (●) caseinolytic activity. The black bar in the ﬁrst peak corresponds to the
ilver stained. Lane 1—molecular mass markers, Lane 2— puriﬁed BJ-PI2. (E) RP-HPLC
he elution proﬁle was monitored at 280 nm. (F) Molecular mass of BJ-PI2 in non-reducing
w/v) dithiothreitol (DTT) and Lane 3 — in the presence of 0.1% (w/v) β-mercaptoethanol.
nomer. M—molecularmass markers (in kDa): 97— phosphorylase b, 66— albumin, 45—
Coomassie blue stained gel.
mass








Fig. 2. Molecular mass determination of native (non-reduced) BJ-PI2 by electrospray-ionization (ESI) mass spectrometry. The spectrum was obtained with a Quadrupole
time-of-ﬂight mass spectrometer (Q-TOF Ultima, Waters). Deconvolution of the spectrum yielded an isotope-averaged molecular mass of 23080.5 Da for the most intense signal.
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run at 6 °C using a three-phase electrophoresis program: 300 V for
1 min, 3500 V for 1.5 h and 3500 V for 3.5 h. Prior to running the second
dimension, the IPG strips were placed in glass tubes and the proteins
in the strip were reduced and alkylated by sequential incubation in the
following solutions: (a) 0.05 M Tris–HCl, pH 8.8, 2% SDS, 30% glycerol,
6 M urea, 0.002% bromophenol blue (equilibration buffer — EB), (b)
10 mgof dithiothreitol/ml in EB and then (c) a solution of iodoacetamide
(25 mg/ml) in EB. The strips were then applied directly to 15% SDS poly-
acrylamide gels (14 cm×16 cm) for second-dimension electrophoresis
at 300 V for 6 h. The gels were subsequently ﬁxed and stained with
silver.
2.6. In-gel protein digestion and mass spectrometric protein identiﬁca-
tion by LC-MS/MS
The protein band was excised and in-gel trypsin digestion was done
according to Hanna et al. [33]. An aliquot (4.5 μl) of the resulting peptideA
Fig. 3. 2D electrophoresis of B. jararaca venom (300 μg) (A) and BJ-PI2 (B) (50 μg). Isolectr
(250 μl) containing 7 M urea, 2 M thiourea, 2% CHAPS, 0.5% IPG buffer, 1% bromophenol blu
steps (300 V for 1 min, 3500 V for 1.5 h and 3500 V for 3.5 h). The second dimension was
stained. The bar in (A) corresponds to the position of BJ-PI2.mixture was injected into a trap column (180 μm i.d.×20 mm) packed
with C18 chromatographic medium (Waters, Milford, MA, USA) for
desalting with 100% solvent A (0.1% formic acid) at 5 μl/min for
3 min. Peptides were then eluted onto an analytical C18 column
(75 μm i.d.×100 mm) (Waters) using a 20 min gradient at a ﬂow rate
of 600 nl/min where solvent A was 0.1% formic acid and solvent B was
0.1% formic acid in acetonitrile. The gradient was 0–80% acetonitrile in
0.1% formic acid over 20 min. A QTOF Ultima mass spectrometer
(Waters) was used to acquire spectra. Spray voltage was set at 3.1 kV
and the instrument was operated in data dependent mode in which
one full MS scan was acquired in the m/z range of 200–2000 followed
by MS/MS acquisition using collision induced dissociation of the three
most intense ions from the MS scan. A dynamic peak exclusion was ap-
plied to avoid the same m/z being selected for the next 120 s. The
resulting fragment spectra were processed using ProteinLynx™ soft-
ware (Waters, USA) and pkl* ﬁles were created and searched using
the MASCOT search engine (Matrix Science, UK) against the SwissProt
database restricted to ‘bony vertebrates’ sequences with a parentB
ic focusing gels strips (13 cm; pH 3–10 linear) were immersed in rehydration solution
e and venom prior to use. The ﬁrst dimension (isoelectric focusing) was done in three
done in 15% SDS-PAGE gels (14 cm×16 cm) run at 300 V for 6 h. The gels were silver
Table 1
Summary of the puriﬁcation of BJ-PI2.
Puriﬁcation step Total protein (mg) Total activity (units)a Speciﬁc activity (units/mg) Puriﬁcation (fold) Protein yield (%)
Venom 103.8±3.1 1302±333 12.6±3.6 1 100
Gel ﬁltration (Superdex 75) 11.4±0.4 629±124 54.6±8.9 4.3±0.7 11.8±0.3
Ion exchange (Sepharose Q) 0.469±0.21 93.9±4.9 200.2±10.6 15.9±0.8 0.45±0.18
a Proteolytic activity with casein as substrate. The values are the mean±SD of three puriﬁcations.
1813I.R.F. da Silva et al. / Biochimica et Biophysica Acta 1820 (2012) 1809–1821tolerance of 1.2 Da and fragment tolerance of 0.6 Da. Iodoacetamide de-
rivatives of cysteine and oxidation of methionine were speciﬁed in
MASCOT as ﬁxed and variable modiﬁcations, respectively.
2.7. Protein quantiﬁcation
Protein concentrations were determined by the method of Lowry
et al. [34] using bovine serum albumin as the standard.
2.8. Enzymatic assays
2.8.1. Caseinolytic activity
Caseinolytic activity was assayed according to Kunitz [35]. Brieﬂy,
1.9 ml of 1% casein in 0.1 M Tris–HCl, pH 7.8, was incubated with
0.1 ml of sample (50 μg of venom or puriﬁed protein) for 20 min at
37 °C. The reaction was stopped by adding 2 ml of 5% trichloroacetic
acid and the tubes then stored on ice for 30 min prior to centrifuga-
tion (2500 g, 15 min, 25 °C). The absorbance of the supernatant was
read at 280 nm in a Beckman DU800 spectrophotometer. One unit
of activity was deﬁned as an increase in absorbance (A280nm) of
0.001/min.
2.8.2. Esterase activity
Esterase activity was assayed using Nα-p-tosyl-L-arginine ester
(TAME) [36]. The reaction mixture consisted of 1.5 ml of substrate
(1 mM TAME in 0.1 M Tris–HCl, pH 7.8), 1.4 ml of 0.1 M Tris–HCl,
pH 7.8, and 0.1 ml of sample (40 μg venom or 40 μg puriﬁed protein).
The mixture was incubated for 10 min at 25 °C after which the absor-
bance was measured at 253 nm. One unit of activity was deﬁned as an
absorbance increase of 0.001/min.
2.8.3. Elastase activity
Elastase activity was assayed using elastin-Congo red and n-t-
boc-L-alanine p-nitrophenol ester as substrates. For the elastin-Congo
red assay [37], the substrate was suspended (1 mg/ml) in 0.05 M so-
dium phosphate, pH 7.2, and 100 μl of this suspensionwas incubated
with 100 μl of sample containing 10 μg of venom or 40 μg of puriﬁed
protein for 18 h at 37 °C. After centrifugation (10,000 g, 15 min,
8 °C), the absorbance of the supernatant was read at 490 nm. One
unit of activity was deﬁned as an increase in absorbance (A490nm)
of 0.001/min.Table 2
Mass spectrometric data for the tryptic peptides of BJ-PI2.
m/z observed (precursor ion) z Peptide sequencea Ion scoreb Deltac
422.74 +2 DXXBVEK 44 −0.0185
449.75 +2 ERDXXPR 50 −0.0129
547.73 +2 YNSNXNTXR 63 −0.0193
782.36 +2 VHEMVNTXNGFFR 62 −0.0601
847.40 +2 YXEXAVVADHGMFTK 85 −0.0531
691.33 +2 TXTSFGEWRER 53 −0.0330
548.75 +2 TXTSFGEWR 57 −0.0315
448.89 +3 BSVAVVMDHSXK 18 −0.0242
a X indicates Leu/Ile, B indicates Gln/Lys and M indicates oxidized Met.
b Mascot ion score.
c Difference between theoretical and observed mass.Activity towards the synthetic substrate n-t-boc-L-alanine p-
nitrophenyl ester was assayed according to Berlov et al. [38]. The
assay mixture consisted of 150 μl of 0.05 M phosphate buffer,
pH 7.2, containing substrate (0.2 mM) and 50 μl of buffer (blank)
or sample (10 μg of venomor 40 μg of puriﬁedprotein diluted in buffer)
in a 96-well plate that was incubated at 37 °C for 30 min during
which the increase in absorbance at 348 nm was measured in a
SpectraMax340 microplate reader (Molecular Devices, Sunnyvale,
CA, USA). The amount of product formed was determined from a
standard curve of p-nitrophenol and one unit of activity corresponded
to the release of 1 mmol of p-nitrophenol/min.
2.8.4. Fibrinogenolytic activity
Fibrinogenolytic activity was assayed by incubating 100 μl of
plasminogen-free bovine ﬁbrinogen (5 mg/ml; dissolved in 0.1 M
Tris–HCl, pH 7.5, containing 0.1 M NaCl) with 100 μl of sample
(10 μg of venom or puriﬁed protein) at 37 °C. At predetermined
times (0, 5, 10 and 30 min, and 1, 2, 4 and 6 h) after sample addition,
20 μl aliquots were withdrawn from the incubation mixture and
transferred to polypropylene Eppendorf tubes containing 20 μl of
2% β-mercaptoethanol and 2% SDS. After mixing, the samples were
loaded onto 12.5% polyacrylamide gels and the proteins separated
by SDS-PAGE (see Section 2.4); the gels were subsequently stained
with Coomassie brilliant blue R250 [39]. Undegraded ﬁbrinogen
and molecular mass markers were included in the runs to allow as-
sessment of ﬁbrinogen chain digestion. In some assays, the puriﬁed
protein was treated with protease inhibitors (10 mM EDTA, 5 mM
1–10 phenanthroline or 5 mM PMSF) for 10 min at 37 °C prior to in-
cubation with ﬁbrinogen. The remainder of the assay was then done
as described above.
2.8.5. Fibrinolytic activity
Fibrinolytic activity was assayed as described by Maruyama et al.
[19]. Petri dishes were poured with molten 1% agarose in 0.1 M
Tris–HCl, pH 7.5, containing 0.1 M NaCl and 0.5% plasminogen-free
bovine ﬁbrinogen. Immediately prior to pouring, 30 μl of thrombin
(1 U/μl) was added to the mixture to clot the ﬁbrinogen. Subsequent-
ly, 10 μl of venom or puriﬁed protein was added to wells cut in the
agarose followed by incubation for 24 h at 37 °C. The diameters of
the resulting halos were measured. One unit of activity corresponded
to a halo diameter of 1 cm.
2.9. Biological activities
2.9.1. Hemorrhagic activity
Hemorrhagic activity was assayed according to Theakston and
Reid [40]. Male Wistar rats were anesthetized with sodium thiopen-
tal (30 mg/kg, i.p.) and the dorsal region was shaved. Venom
(4.5, 13.5 and 45.0 μg) or puriﬁed protein (10 and 40 μg) diluted in
0.01 M Tris–HCl, pH 8.0, containing 0.01 M CaCl2 was injected intra-
dermally (ﬁxed volume of 100 μl) and control sites were injected
with Tris–HCl/CaCl2 buffer alone. After 24 h, the rats were killed
with an overdose of isoﬂurane, the dorsal skin was removed and
the diameter of the hemorrhagic halo on the inner surface of the
skin was measured. The minimum hemorrhagic dose (MHD)was de-
ﬁned as the amount of venom or enzyme capable of producing a
hemorrhagic halo 1 cm in diameter.
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Male Swiss mice were injected with B. jararaca venom (40 μg),
puriﬁed protein (40 μg) or 0.01 M Tris–HCl, pH 8.0, containing
0.01 M CaCl2 (control) in the right gastrocnemius muscle. At 3, 6, 12
and 24 h post-injection the mice were killed with isoﬂurane and
blood samples were obtained for the quantiﬁcation of plasma crea-
tine kinase (CK) activity with commercial kits (LaborLab, Guarulhos,
SP, Brazil); the gastrocnemius muscle was also removed at these
same intervals for histological analysis.
2.9.3. Vascular permeability assay
Male Wistar rats were anesthetized with sodium thiopental
(50 mg/kg, i.p.) and maintenance doses were administered when re-
quired. Local plasma protein extravasation was measured in the
shaved dorsal skin, in response to intradermally injected B. jararaca
venom(3–10 μg/site), puriﬁed protein (1–30 μg/site) or Tyrode solution
(100 μl) [41]. Agentswere injected in a randomorder, according to a bal-
anced site pattern. Plasma protein extravasation was measured by the
accumulation of intravenously (i.v.) injected 125I-human serum albumin
(2.5 μCi/rat)with Evan's blue dye (20 mg/kg) serving as a visualmarker.
After 30 min, a cardiac blood sample (1 ml)was obtained from anesthe-
tized rats that were then killed with an anesthetic overdose. The blood
was transferred to polypropylene tubes containing 100 μl of heparin
and then centrifuged (10,000 g, 8 min, room temperature) to obtain
plasma. The dorsal skin was removed from the rats and the injected
sites were punched out and counted for radioactivity, together
with plasma samples, in a gamma-counter. Plasma extravasation
was expressed as the volume (μl) of plasma accumulated at each
skin site compared to total counts in 1 ml of plasma. In someexperiments,
the puriﬁed protein was preincubated with 5 mM 1,10-phenanthroline
for 10 min at 37 °C prior to injection into dorsal rat skin.
2.9.4. Coagulant activity
2.9.4.1. Fibrinogen clotting in vitro. The ability of BJ-PI2 to clot ﬁbrino-
gen in vitro was assayed by incubating 180 μl of plasminogen-free bo-
vine ﬁbrinogen (5 mg/ml; dissolved in 0.1 M Tris–HCl, pH 7.5,
containing 0.1 M NaCl) with 20 μl of sample (40 μg of venom, 40 μg
of BJ-PI2 or 20 U of thrombin) and the time required to clot at 37 °C
was recorded.
2.9.4.2. Clotting of rat citrated plasma. The coagulant activity of venom
and BJ-PI2 was examined using rat citrated platelet-poor plasma (PPP).
Rat arterial blood was collected into polypropylene tubes containing
3.8% sodium citrate (anticoagulant:blood ratio 1:9, v/v). Platelet-rich
plasma (PRP) was obtained by centrifugation (400 g, 20 °C, 15 min);
PRP was then centrifuged (800 g, 20 °C, 13 min) to obtain PPP that
was used in the coagulation test. For the assay, 190 μl of PPPwas incubat-
ed at 37 °Cwith 10 μl of sample (thrombin: 0.3 U; venom: 40 μg; PI-BJ2:
10 or 40 μg) and the time required for clot formation was recorded.
2.9.4.3. Plasma recalciﬁcation. The inﬂuence of BJ-PI2 on the plasma
recalciﬁcation time was assayed as described by Berger et al. [31],
with some alterations. Brieﬂy, platelet poor plasma (PPP) was
obtained from citrated rat blood by centrifugation (3000 g, 15 min,
room temperature) and 50 μl aliquots were transferred to a 96-well
microplate and incubated with 50 mM Tris–HCl, pH 7.4 (control) or
BJ-PI2 (5 or 10 μg) in Tris–HCl buffer at 37 °C. After a 5 min incuba-
tion with BJ-PI2, 10 μl of 250 mM CaCl2 was added to each well andFig. 4. Sequences of BJ-PI2 fragments identiﬁed by mass spectrometry and a database search
insularinase A and bothrojaractivase identiﬁed in this work. Amino acids with a single underline
identiﬁed by Zelanis et al. [46] and amino acids in bold with a double underline — amino acids i
the proteins in this table are P83512.2 for BaP1 [44], Q5XUW8.1 for insularinase A [42], P0C7A9.1
IV [43]. Note that the jararaﬁbrase II sequence is containedwithin themetalloproteinase domain o
from Oliveira et al. [24] as they are not available through the UniProtKB/Swiss-Prot database. X inclot formation was monitored for 30 min at 650 nm in a SpectraMax
340 microplate reader (Molecular Devices).
2.10. Statistical analysis
The results were expressed as the mean±SD. Statistical compari-
sons were done using Student's t-test or ANOVA followed by the
Bonferroni test. Values of pb0.05 indicated signiﬁcance.
3. Results
3.1. Puriﬁcation of BJ-PI2 from B. jararaca venom
Fractionation of B. jararaca venom on Superdex 75 resulted in four
peaks, two of which had caseinolytic activity (Fig. 1A). The second of
these peaks contained proteins with molecular masses of 20–35 kDa
(by SDS-PAGE) (Fig. 1B) and was used in subsequent puriﬁcations.
Fractionation of the second peak by anion exchange chromatography
(Hitrap Sepharose Q) yielded ﬁve peaks, the ﬁrst of which eluted be-
fore the salt gradient and contained caseinolytic activity (Fig. 1C);
reverse-phase HPLC of this peak conﬁrmed its purity (Fig. 1E).
SDS-PAGE of this peak revealed a single protein band of 25.2 kDa
(Fig. 1D) that was unaltered by reducing conditions (DTT or
β-mercaptoethanol) (Fig. 1F). Mass spectrometry yielded a series of
closely grouped signals that differed by a maximum of 482 Da; the
most intense of these signals corresponded to a mass of 23.08 kDa
(Fig. 2), which was similar to the value of ~25 kDa obtained by
SDS-PAGE. Two-dimensional gel electrophoresis indicated that the
protein was basic (pI ~8) (Fig. 3). Table 1 summarizes the puriﬁca-
tion protocol. BJ-PI2 corresponded to 0.45% of the venom protein
and had a speciﬁc activity of 200.2±10.6 units/mg (venom speciﬁc
activity: 12.6±3.6 units/mg; puriﬁcation factor of ~16%, based on
the proteolytic/caseinolytic activity).
3.2. Identiﬁcation of BJ-PI2 by mass spectrometry of tryptic fragments
Mass spectrometric analysis of a tryptic digest of the puriﬁed protein
yielded eightMS/MS spectra with low background noise that provided in-
formation on the b and y-ion series. A database searches identiﬁed the
fragmentsYIELAVVADHGMFTK, YNSNLNTIR, VHEMVNTLNGFFR,DLIKVEK,
TLTSFGEWR, TLTSFGEWRER, ERDLLPR and QSVAVVMDHSKK. Table 2
shows the m/z and z of the precursor ions and other information for the
peptide fragments identiﬁed by mass spectrometry. These fragments
showed highest homology with the SVMP insularinase A from Bothrops
insularis (UniProtKB/Swiss-Prot accession number Q5XUW8.1; [42]) but
also shared homology with the B. jararaca SVMP bothrojaractivase
(accession number P0C7A9.1; [31]); less similarity was observed
with the B. jararaca SVMPs BJ-PI (peptide sequences from [24]) and
jararaﬁbrases II and IV (accession numbers Q98SP2.1 and P0C6S6.1,
respectively; [19,43]); there was also some homology with BaP1, a P-I
SVMP from B. asper venom (accession number P83512.2; [44]) (Fig. 4).
Basedon this analysis andon additionalﬁndingsdescribedbelow, this pro-
tein was identiﬁed as a P-I SVMP and named BJ-PI2, to avoid confusion
with the previously identiﬁed BJ-PI, another P-I class metalloproteinase
in B. jararaca venom [24].
3.3. Enzymatic and biological activities
In addition to the proteolytic activity indicated in Section 3.1, BJ-PI2
(40 μg) degraded the substrate elastin-Congo red (128.8±5.2 units/mg: comparison with other Bothrops P-I SVMPs. In gray, fragments showing homology with
— tryptic fragments identiﬁed by Zelanis et al. [45], amino acids in bold — tryptic fragments
n bothrojaractivase that differ from BJ-PI2. The UniProtKB/Swiss-Prot accession numbers for
for bothrojaractivase [31], Q98SP2.1 for jararaﬁbrase II [19,43] and P0C6S6.1 for jararaﬁbrase
f the gene encoding for the disintegrin bothrostatin [47]. The fragment sequences for BJ-PI are
dicates Leu/lle, B indicates Gln/Lys.
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was less active towards the synthetic elastase substrate n-t-boc-L -
alanine p-nitrophenyl ester (10.8±7.7 units/mg compared to 131.5±
27.7 units/mg for 40 μg of venom; n=3). BJ-PI2 had no esterase activ-
ity (venom esterase activity: 282.0±22.6 units/mg; n=3).
BJ-PI2 (40 μg) did not clotﬁbrinogen in vitro, in contrast to B. jararaca
venom (40 μg) and thrombin (20 U) which produced clots in 12±1 s
and 20±1 s, respectively (n=3 each). In agreement with this ﬁnding,
BJ-PI2 (40 μg) also did not clot rat citrated plasma, in contrast to
B. jararaca venom (40 μg; 42±11 s, n=5) and thrombin (0.3 U;
281±38 s, n=5). Although BJ-PI2 (40 μg) did not clot rat citrated plas-
ma itwas neverthelessﬁbrinogenolytic and cleaved theα chain ofﬁbrin-
ogen very rapidly (within 10 min)while the β chainwas degradedmore
slowly (within 30 min); there was limited digestion of the γ chain
(Fig. 5A). This ﬁbrinogenolytic activity was inhibited by 1,10-
phenanthroline and EDTA but not by PMSF (Fig. 5B), indicating that
BJ-PI2 is a metalloproteinase (rather than a serine proteinase). BJ-PI2
(10 μg) attenuated the rate of coagulation during plasma recalciﬁcation,
as judged from the inclination of the ascending portion of the curve, and
markedly reduced the extent of coagulation without affecting the time
for the initiation of coagulation; a lower amount of BJ-PI2 (5 μg) did
not affect coagulation in response to recalciﬁcation (Fig. 6). BJ-PI2
(10 μg) was also ﬁbrinolytic (halo of 3.2±0.7 cm in the ﬁbrin plate
assay compared to 6.3±0.0 cm for 10 μg of venom).
BJ-PI2 caused a dose-dependent increase in vascular permeability in
rat dorsal skin (Fig. 7A) that was abolished by preincubating the protein
with 1,10-phenanthroline (Fig. 7B). BJ-PI2 (40 μg)was not hemorrhagic
in rat dorsal skin (halob0.1 cm) whereas a venom dose of 40 μg pro-
duced a hemorrhagic halo of 1.2±0.2 cm (the MHD for venom was
20.7 μg). The intramuscular injection of BJ-PI2 (40 μg) did not cause
myonecrosis, assessed either as an increase in circulating CK levels or
as histological damage; in contrast, venom (40 μg) produced a marked
increase in CK levels and extensive histological damage (hemorrhage
and necrosis) (Fig. 8). Although BJ-IP2 was not hemorrhagic, it caused
marked inﬁltration of inﬂammatory cells 3, 6 and 12 h after injection
compared to control (saline) and venom-treated mice.
4. Discussion
B. jararaca is responsible for most bites by Bothrops spp. in Brazil,
particularly in the southeast of the country. Envenoming by this species
results in local edema, hemorrhage and necrosis, while themost common
systemic manifestations are hemostatic disturbances (coagulopathy and
platelet dysfunction) and systemic hemorrhage that are shared with
other species of the genus [6–10]. Several of these local and systemic ef-
fects are mediated by SVMPs [2,4,7,10,11].
The current classiﬁcation of SVMP includes three major classes
(P-I, P-II and P-III) and some subclasses, with the most hemorrhagic
toxins belonging to P-III class and those with weakest activity belong-
ing to P-I class [1,2,4,48]. Various P-I class SVMPs have been puriﬁed
and characterized from B. jararaca venom, including jararaﬁbrases II,
III and IV [19,30], bothrojaractivase [31] and BJ-PI [24]. These SVMPs
and related proteins isolated from other Bothrops spp. have a molec-
ular mass of ~20–27 kDa and are generally ﬁbrino(geno)lytic, but
show variable hemorrhagic and myotoxic activities (Table 3).
The results described here and a comparison with data in the liter-
ature indicate that we have identiﬁed a new non-hemorrhagic P-I
metalloproteinase (BJ-PI2, ~25 kDa by SDS-PAGE and 23 kDa by
mass spectrometry) from B. jararaca venom. The protein was puriﬁed
in two chromatographic steps (gel ﬁltration on Superdex 75 followed
by anion exchange chromatography on Sepharose Q) and yielded a
single band in SDS-PAGE and a single symmetrical peak in HPLC.
Mass spectrometry revealed a series of associated peaks (maximum
mass difference of 482 Da), possibly indicative of closely related
isoforms that differ in a few amino acids or in post-translational mod-
iﬁcations. BJ-PI2 was inhibited by EDTA and 1,10-phenanthroline(metalloproteinase inhibitors) but not by PMSF (a serine proteinase
inhibitor); this inhibition proﬁle was similar to that for other Bothrops
P-I SVMPs [52–55,57,58,63].
The analysis of tryptic fragments indicated that BJ-PI2 shared
greatest homology with insularinase A, a P-I class SVMP isolated
from B. insularis venom [42]. Previous transcriptomic [65,66] and pro-
teomic [45,46] analyses of B. jararaca venoms from neonates and
adults have also identiﬁed proteins related to insularinase A, but
this protein has not previously been isolated and studied. Analysis
of Table 2 and Fig. 4 shows that seven of the eight fragments identi-
ﬁed here were previously identiﬁed by Zelanis et al. [45,46]; the
eighth (BSVAVVMDHSBB) fragment identiﬁed here was new. Frag-
ments not detected here but identiﬁed in previouswork [45,46] include
ASXANXEVWSB, SCXMASTXSB, ABCAEGXCCDBCR, CTGBSADCPR and
GDNPDDRCTGBSADCPR (see Fig. 4). Together, these sequences indicate
that BJ-PI2 is structurally related to insularinase A.
BJ-PI2 accounted for 0.45% of the total venomprotein. This yield was
similar to that for other P-I SVMPs from B. jararaca venom (except for
BJ-PI), but lower than for several other Bothrops P-I SVMPs (Table 3).
Adult specimens of B. jararaca can yield up to 150 mg of venom
[67–69] that would theoretically contain ~0.675 mg or 675 μg of
BJ-PI2. Based on the results described above, this amount of BJ-PI2
would be sufﬁcient to produce the local effects observed in this work
since inmost of the experiments only 10–40 μg of the proteinwas used.
Envenoming by B. jararaca is characterized by hemostatic distur-
bances, including blood incoagulability and platelet dysfunction
[7,70,71], and proteins capable of interfering with the coagulation cas-
cade and platelet aggregation have been identiﬁed in the venom of
this species [18,72]. Although BJ-PI2 did not clot ﬁbrinogen or rat
citrated plasma, i.e., no thrombin-like activity leading to clot formation,
this protein was strongly ﬁbrinogenolytic in vitro, with the preference
for chain cleavage being α>β. This chain selectivity was similar to
that observed for bothrojaractivase [31] and jararaﬁbrase II [19] from
B. jararaca and Batx-I from Colombian Bothrops atrox [53]. Indeed,
most Bothrops P-I SVMPs are α/β ﬁbrinogenases, although some of
them are essentially α-ﬁbrinogenases (Table 3). This divergence in
the susceptibility of ﬁbrinogen chains to degradation may partly reﬂect
variations in the SVMP concentration and incubation times tested. The
strong ﬁbrinogenolytic activity of BJ-PI2 resulted in a decrease in the
rate and extent of recalciﬁcation that reﬂected substrate depletion by
this protein. Like other Bothrops P-I SVMPs (Table 3), BJ-PI2 was also ﬁ-
brinolytic. Together, these activities could contribute to coagulopathy
after envenoming by B. jararaca. Although some P-I SVMPs are inhibited
byα2-macroglobulin [52,73] this was probably not the case with BJ-PI2
since in plasma the protein was still able to degrade ﬁbrinogen and
markedly reduce the extent of coagulation during plasma recalciﬁcation.
P-I class SVMPs vary in their ability to cause hemorrhage (Table 1),
and those that do cause hemorrhage are only weakly so, especially
when compared to P-III SVMPs [4]. As shown here, in contrast to the
venom, BJ-PI2was not hemorrhagic and therefore probably contributes
little to this effect of the venom. However, hemorrhagic activity may
vary with the route of administration. Thus, for example, neuwiedase
(a P-I SVMP from Bothrops neuwiedi) is not hemorrhagic in mouse
skin or gastrocnemius muscle but causes hemorrhage when applied
topically to exposed mouse cremaster muscle (as assessed by intravital
microscopy) and in lungs (but not other internal organs) after i.v. ad-
ministration [64].
The limited hemorrhagic activity of P-I SVMPs compared to P-III
SVMPs has been attributed to the poor ability of the former toxins
to bind and cleave basement membrane proteins such as collagen IV
[4,74] and their susceptibility to inhibition by circulating proteins
such as α2-macroglobulin [4]. The presence of carbohydrate moieties
and of disintegrin-like, cysteine-rich and C-type lectin domains in
P-III SVMPs may also be important factors in their hemorrhagic activ-
ity [4,25]. The ability to cause hemorrhage is frequently related to the




























Fig. 5. Fibrinogenolytic activity of BJ-PI2. (A) Time-course ofﬁbrinogenolytic activity of BJ-PI2
(10 μg). At the times indicated on the X-axis ﬁbrinogen chain degradation was assessed by
withdrawing samples from theﬁbrinogen-BJ-PI2mixture (incubated at 37 °C) and analyzing
them by SDS-PAGE. BJ-PI2 cleaved the Aα chain ﬁrst, followed by the Bβ chain; the γ chain
was relatively resistant to digestion. (B) Inﬂuence of protease inhibitors on ﬁbrinogenolytic
activity of BJ-PI2 (10 μg). Lane 1 — ﬁbrinogen incubated without BJ-PI2 showing all of the
chains (α, β and γ), Lane 2 — ﬁbrinogen+BJ-PI2, Lane 3 — ﬁbrinogen+BJ-PI2
pre-incubated with 5 mM 1,10-phenanthroline, Lane 4— ﬁbrinogen+BJ-PI2 pre-incubated
with 5 mMPMSF and Lane 5—ﬁbrinogen+BJ-PI2 preincubatedwith 1 mMEDTA. The incu-
bation time of ﬁbrinogen with BJ-PI2 in these experiments was 360 min. In both panels, the
samples were run in 12.5% polyacrylamide gels (SDS-PAGE) that were subsequently stained
with Coomassie brilliant blue. M — molecular mass markers (in kDa). See Fig. 1 legend for
marker identiﬁcation.



















Fig. 6. BJ-PI2 (10 μg) attenuates the rate and extent of coagulation during plasma
recalciﬁcation. Plasma samples (50 μl) were preincubated with 50 mM Tris–HCl,
pH 7.4 (control) or BJ-PI2 (5 μg or 10 μg in Tris–HCl buffer) in a 96-well microplate
at 37 °C for 5 min prior to the addition of 10 μl of 250 mM CaCl2 to each well. Clot for-
mation was monitored for 30 min at 650 nm in a microplate reader. The results are
expressed as a percentage of the maximum clotting observed after recalciﬁcation in
control plasma samples treated with Tris–HCl buffer alone. The points are the
mean±SD (n=3 independent experiments using plasma from three rats).
Fig. 7. Increase in vascular permeability caused by BJ-PI2. (A) Dose‐response curve to
BJ-PI2. (B) Inhibition of the increase in vascular permeability by 1,10-phenanthroline.
BJ-PI2 (10 μg) was pre-incubated with 5 mM 1,10-phenanthroline for 10 min at 37 °C
prior to injecting into mouse dorsal skin. Pre-incubation with 1,10-phenanthroline signif-
icantly (pb0.05) attenuated the increase in vascular permeability. In (A) and (B), the
points or columns are the mean±SD of n=5. *pb0.05 compared to Tyrode alone and
1,10-phenanthroline (phen) alone. #pb0.05 compared to BJ-PI2+phen.
1817I.R.F. da Silva et al. / Biochimica et Biophysica Acta 1820 (2012) 1809–1821are unable to disrupt vessel walls by degrading the ECM generally pro-
voke little or no hemorrhage. On the other hand, a synergistic action be-
tween hemostatic disturbances and direct damage to the vessel by
hemorrhagic toxins can result in hemorrhage [4,11]. In the case of
BJ-PI2, although this protein had ﬁbrino(geno)lytic activity (that could
cause coagulation disturbances), it did not cause hemorrhage, possibly
because of limited degradation of ECM proteins, as suggested for
non-hemorrhagic P-I SVMPs [4,74]. Although BJ-PI2 was active towards
the synthetic elastase substrate n-t-boc-L-alanine p-nitrophenyl ester
and the natural substrate elastin-Congo red this activity probably
reﬂected a non-speciﬁc proteolytic action of BJ-PI2 rather than true
elastase activity since B. jararaca venom shows no activity towards the
highly speciﬁc elastase substrates n-methoxysuccinyl-Ala-Ala-Pro-Val-
p-nitroanilide and n-succinyl-Ala-Ala-Ala-p-nitroanilide (unpubl. obs.).
Bothrops venoms are frequently myotoxic and this activity is me-
diated primarily by myotoxic PLA2, with SVMPs exerting a less
1818 I.R.F. da Silva et al. / Biochimica et Biophysica Acta 1820 (2012) 1809–1821prominent role. As with hemorrhagic activity, P-I SVMPs vary in their
ability to cause myonecrosis (Table 3). As shown here, BJ-PI2 was not
myotoxic (as assessed by CK release and histological damage) and is
therefore unlikely to be an important venom component in this re-
















Fig. 8. Assessment of tissue damage by BJ-PI2. (A) Circulating plasma CK levels in mice injec
pH 7.5 (20 μl, ﬁxed volume used to inject venom or toxin). Mice were inoculated in the gastr
tiﬁcation of plasma CK levels. The points are the mean±SD (n=4). (B–J) Histological chang
(D,G,J). At the times indicated above, the muscle was removed, ﬁxed in buffered 10% fo
hematoxylin-eosin (HE). (B–D) represent mice 3 h post-injection, (E–G) 6 h post-injection a
and inﬂammatory cells, respectively.jararacussu [54] and BnP1 from B. neuwiedi [62], are also not myotoxic
and contribute little to this action in their respective venoms.
Although not hemorrhagic or myotoxic, BJ-PI2 markedly stimulat-
ed the inﬁltration of inﬂammatory cells 3, 6 and 12 h after injection.












ted intramuscularly with B. jararaca venom (40 μg), BJ-PI2 (40 μg) or 0.01 M Tris–HCl,
ocnemius muscle and blood samples were obtained at 0, 3, 6, 12 and 24 h for the quan-
es in gastrocnemius muscle injected with saline (control; B,E,H), venom (C,F,I) or BJ-PI2
rmol and processed for histological analysis. Sections 5 μm thick were stained with
nd (H–I) 12 h post-injection. *, H and arrows represent myonecrotic ﬁbers, hemorrhage
Table 3
Comparison of the properties of BJ-PI2 and other P-I metalloproteinases isolated from B. jararaca and other Bothrops spp. venoms.
Species Enzyme Fibrinolytic Fibrinogenolytic Hemorrhagicb Edematogenic Myonecrotic Yield (%) Mass (kDa) References
B. jararaca BJ-PI2 Yes Yes (α/β chains) No Yes No 0.45 23.1 This work
BJ-PI a Yes (α chain) No a a 14 22.0 [24,25]
Bothrojaractivase Yes Yes (α/β chains) a a a 0.19 22.8 [31]
Jararaﬁbrase II Yes Yes (α/β chains) Yes a a 0.35 21.4 [19]
Jararaﬁbrase III Yes a Yes a a a 20.4 [30]
Jararaﬁbrase IV Yes a Yes a a a 21.2 [30]
B. asper BaP1 a Yes (α/β chains) Yes Yes Yes a 24.0 [49,50]
BH2 a a Yes a a a 26.0 [51]
B. atrox Atroxlysin-I Yes Yes (α chain) Yes a a 5.1 23.0 [52]
Batx-1 a Yes (α/β chains) Yes a Yes 45 23.3 [53]
B. insularis Insularinase A Yes Yes (α/β chains) No a a a 22.6 [42]
B. jararacussu BjussuMP-II Yes Yes (α/β chains) No Yes No a 24.0 [54]
B. leucurus Leucurolysin-a Yes Yes (α/β chains) No Yes a 5.4 23.0 [55,56]
B. marajoensis BmHF-1 a Yes (α chain) Yes Yes No 8–10 27.2 [57]
B. moojeni BthMP Yes Yes (α/β chains) Yes Yes Yes 2.3 23.5 [58]
BmooMPα-I Yes Yes (α/β chains) No a a 8.7 23.1 [59]
Moojeni protease A Yes Yes (α/β chains) No a a 2.4 20.4 [60,61]
B. neuwiedi BnP1 Yes Yes (α/β chains) Yes a No a 24.0 [62]
Neuwiedase Yes Yes (α/β chains) Noc Yes Yes 4.0 22.4 [63,64]
a Not determined/not reported.
b The toxins with activity are only weakly hemorrhagic.
c No hemorrhage in mouse dorsal skin or gastrocnemius muscle, but bleeding observed by intravital microscopy after local application to mouse cremaster muscle and hemor-
rhage in lungs after i.v. injection [64].
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this P-I SVMP nevertheless caused a marked inﬂammatory reaction in
mouse gastrocnemius muscle after i.m. administration. Similarly,
Gomes et al. [58] have shown that BthMP from Bothrops moojeni
caused marked leukocyte inﬁltration in this same animal model,
with a gradual return to normal after 24 h. The local inﬂammatory re-
sponse seen with neuwiedase apparently involved enhanced cytokine
(IL-1β, IL-6 and KC — a murine functional homolog of human IL-8)
production (sustained for up to 8 h in the case of IL-1β) by skeletal
muscle [75]; variable increases were also observed for IL-6, KC and
TNFα in murine peritoneal adherent cells (MPACs) and C2C12 cells
(a skeletal muscle cell line), depending on the cell type. BaP1, a hem-
orrhagic P-I SVMP from B. asper venom, also enhances IL-1 and IL-6
production (but not TNF-α or IFN-γ levels) in mouse skeletal muscle
[15]. A similar action by BJ-PI2 could account for the ability of this
toxin to increase inﬂammatory cell migration into muscle and en-
hance vascular permeability.
In conclusion, we have isolated and characterized a new
metalloproteinase (BJ-PI2) in B. jararaca venom. The actions of this
toxin on vascular permeability and inﬂammatory cell migration indi-
cate that BJ-PI2 is involved in these local responses in vivo. In
contrast, BJ-PI2 appears to have little role in venom-induced hemor-
rhage and necrosis. In view of current interest in the hemostatic ac-
tions of snake venom components, the ﬁbrin(ogen)olytic activity of
BJ-PI2, coupled with its lack of hemorrhagic and necrotic activity,
makes this protein a potentially interesting molecule for studies of
its possible therapeutic application in thrombotic disorders.
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